Our study identified some novel potential targets in the NAFLD/ATH axis, including ADAMTS1, ADAMTS, CEBPA, and CSF3, using mainly bioinformatics tools. The gene discussed is CSF3; the disease is metabolic dysfunction-associated steatotic liver disease.